The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma

The current landscape of frontline DLBCL trialsПодробнее

Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with NHL and CLLПодробнее

Potential Benefits of Selinexor for CAR-T TherapiesПодробнее

The role of CAR T-cell therapy for treating myeloma in the era of bispecific antibodiesПодробнее

CAR T-Cell Therapy Advances in Large B-Cell LymphomaПодробнее

Patient Forum: CAR T-Cell Therapy & Scleroderma – Today and Future (2024)Подробнее

Patient Living with Follicular Lymphoma Benefits from Innovative ApproachesПодробнее

The promise of immunotherapies in T-cell lymphomaПодробнее

Immuno-Oncology Market 2024: Innovations, Growth, and Trends in Cancer Immunotherapy and TreatmentsПодробнее

Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in R/R multiple myelomaПодробнее

Multiple Myeloma Treatments: How Close Are We To a CURE? | The Patient StoryПодробнее

Treating Lymphoma with Bispecific Antibodies | LRF WebinarsПодробнее

What are Trispecific antibodies?Подробнее

The benefits of glofitamab in R/R DLBCL post-CAR-T therapyПодробнее

How Is CAR T-Cell Therapy Research Advancing Myeloma Care?Подробнее

Update on Follicular Lymphoma | LRF WebinarsПодробнее

CAR T cell therapy in New Zealand - Dr Robert WeinkoveПодробнее

What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?Подробнее

Non-Hodgkin Lymphoma: First Symptoms, Diagnosis & the LATEST Treatments | The Patient StoryПодробнее

What are the side effects and difficulties with new myeloma immune therapies?Подробнее